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L IVER transplantation (OL T) has now emerged as the treatment of choice for many patients with end-stage 
liver disease. and the number of centers performing OLT 
has grown tremendously over the last 5 years. Standardi-
zation of surgical techniques and the routine use of veno-
venous bypass combined with improvements in organ 
preservation and immunosuppression have resulted in 
better overall patient survival. Despite these improve-
ments, infections continue to dominate the early postop-
erative period in many patients and account for high 
morbidity and most deaths. 
RISK FACTORS 
Impeccable surgical technique remains the most important 
initial factor in preventing early infectious complications. 
The urgency of transplantation, surgical history, prolonged 
operative time, and excessive blood loss are well-docu-
mented risk factors. Technical complications requiring 
reoperation often increase bacterial and fungal infection 
rates. The need for retransplantation because of severe 
graft dysfunction and rejection or aggressive treatment of 
rejection in itself is a major influence on the subsequent 
development of sepsis in the perioperative period. 
REVIEW OF RECENT STUDIES 
Reports of infections from centers experienced in perform-
ing OL T over the last 5 years are summarized in Table 
1. 1-5 Overall rates of infection varied from 50% to 83%, 
with mortality ranging from 4.6% to 26%. The improve-
ments noted during this interval are multifactorial and 
reflect changes in technique and type of immunosuppres-
sion and overall better perioperative care of patients 
during this time. The high mortality in the early Pittsburgh 
series (26%) has been reduced to 4.6% with the introduc-
tion of a new immunosuppressive agent (FK 506), despite 
a relatively short follow-up period. Immunosuppression 
protocols, which included cyclosporine (CyA) and ste-
roids, were used in the other studies. With the exception of 
the Mayo Clinic. most centers did not use selective bowel 
Table 1. Incidence of Infections and Mortality Over the Last 5 
Years Reported From Liver Transplantation Centers 
Number of Infection Mortality 
Center Date Patients Rate(%) (%) 
Univ. of Pittsburgh 3/88 101 83 26 
Univ. of California (LA) 3/88 35 66 14 
Univ. of Minnesota 12188 93 B.6 
Mayo Clinic' 5/B9 53 75 7.6 
Univ. of Pittsburgh B/90 110 50 4.6 
'With selective bowel decontamination. 
decontamination. In all series, the highest rates of bacterial 
infection were seen in patients with such risk factors as 
rejection. reoperation. and the need for retransplantation. 
and occurred almost exclusively in the first 2 months. 
SELECTIVE BOWEL DECONTAMINATION 
Most infections developing in immunocompromised patients 
arise from endogenous aerobic bacteria. The theoretic con-
cept supporting the use of selective bowel decontamination 
(SBD) relies on the elimination of gram-negative aerobic 
colonizers ("resistance colonization") with preservation 
of the anaerobic flora. The activity of anaerobes in con-
trolling local flora appears to protect patients against 
potential pathogens by limiting their growth in the gut and 
ultimately decreasing serious endogenously derived infec-
tions. Centers engaged in trials of routine use of SBD in 
leukemic and critically ill surgical popUlations report a 
decrease in rates of such infections, but mortality and ICU 
stays are not decreased. Despite many reports on this 
topic, controversy exists regarding the routine use of SBD. 
Concern has been expressed about the- emergence of 
resistant organisms and about patients' compliance. The 
literature on SBD in patients undergoing OLT is sparse. 
This has been championed by the group at the Mayo 
Clinic, where routine SBD is given to all patients from the 
time an active donor search begins and continued through 
the first 3 postoperative weeks. Gram-negative infections 
are virtually eliminated during this period. with gram-
positive organisms dominating those infections that de-
velop during treatment. Rapid colonization with a similar 
spectrum of pretreatment organisms is seen once SBD is 
stopped and does not appear to influence morbidity. The 
Mayo Clinic data suggest that SBD does reduce perioper-
ative gram-negative infection and should probably be used 
in patients undergoing OLT. The issues that require clar-
ification include the timing of SBD, the selection of pa-
tients, the length of treatment. and the agents to be used. 
European centers use a combination of tobramycin and 
amphotericin. whereas the Mayo Clinic uses a gentamicin. 
nystatin. and polymyxin B regimen. The additional ex-
pense of the drugs used in Europe may well become a 
major influence against their ultimate choice in the United 
States. The persistence of significant numbers of gram-
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positive infections will require separate future consider-
ation. 
IMMUNOSUPPRESSION 
Immunosuppression clearly plays a major role in decreas-
ing host resistance to infection. The use of mUltiple drug 
regimens along with antilymphocytic and antithymocytic 
agents results in high infectious morbidity. The avoidance 
of heavy steroid pulses and recycles results in lowered 
rates of serious infections. Our recent experience with FK 
506 is particularly promising, for in many cases, steroids 
can be withdrawn completely and the single agent FK 506 
preserves good graft function. The infectious complication 
rate of the Cy A era was reduced from 83% to 50%. Overall 
mortality was reduced from 25% to 4.6%. reflecting the 
lower rates of retransplantation. reoperation. and rejection 
associated with FK 506. 
LONG-TERM PROPHYLAXIS 
Major changes have also taken place in the use of long-
term prophylaxis to prevent the development of opportu-
nistic infections in these immunocompromised hosts. Pro-
tozoal infections. mainly Pneumocystis carinii. have been 
virtually eliminated in our patients by the daily adminis-
tration of Bactrim for prolonged periods. Low-dose acy-
clovir has significantly decreased herpetic infections. Cy-
tomegalovirus (CMV) infection. however. continues to be 
a major challenge. Among all transplantation patients. 
CMV appears with highest frequency in patients undergo-
ing OLT. The development of symptomatic CMV is asso-
ciated with certain well-established risk factors that in-
clude serologic status of the recipient-donor pairs. degree 
of immunosuppression. and the use of antilymphocyte 
therapy in managing steroid-resistant rejection. A recent 
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randomized double-blind trial comparing high-dose acy-
clovir with placebo in a group of patients undergoing renal 
transplantation reports a significant decrease in rates of 
symptomatic CMV. Preliminary data in our patients given 
FK 506 under a similar protocol have not supported the 
findings in the Minnesota study. Episodes of CMV occur 
as frequently as they did in patients treated with CyA but 
have been associated with fewer deaths. The recent and 
successful addition of DHPG therapy to the management 
of symptomatic CMV infection has shown promise in 
reducing morbidity. Prophylactic treatment trials should 
be undertaken. 
FUTURE DIRECTIONS 
Future improvements in OLT will be directed toward 
decreasing the morbidity associated with this major pro-
cedure. Control of infection will continue to playa domi-
nant role. The deliberate interruption of host defense 
mechanisms by immunosuppressive therapy is a necessary 
evil that requires novel approaches to infection prophy-
laxis. Prospective trials of SBD and improvements in 
antifungal and antiviral protocols are needed to minimize 
the constant threat of uncontrolled infection in these 
patients. 
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